GE HealthCare Technologies Inc. (GEHC) has announced a partnership with Novo Nordisk to create an innovative ultrasound treatment for type 2 diabetes and obesity. By leveraging peripheral focused ultrasound technology, this collaboration aims to regulate metabolic function without the need for pharmaceutical intervention.
According to GE HealthCare, preliminary clinical research suggests that this type of ultrasound can impact glucose metabolism in diabetes patients by stimulating nerve pathways. With over 37 million Americans living with diabetes, and the majority of them having type 2 diabetes, this collaboration has significant potential to revolutionize treatment options.
Roland Rott, President and CEO of GE HealthCare’s ultrasound business, expressed his excitement regarding this collaboration. He sees it as an opportunity to transform ultrasound from a diagnostic tool into a therapeutic solution. By working together, GE HealthCare and Novo Nordisk can pave the way for future advancements in care.
Martin Holst Lange, Executive Vice President and Head of Development at Novo Nordisk, emphasized the importance of exploring ultrasound’s potential in treating type 2 diabetes and obesity. Despite recent progress in these areas, there are still significant unmet needs that must be addressed.
While the terms of the agreement between the two companies were not disclosed, it is worth noting that the underlying technology was developed by scientists at GE HealthCare’s HealthCare Technology and Innovation Center.
GE HealthCare shares rose 0.8% in premarket trading on Thursday and have seen an overall increase of 11.7% this year. In comparison, Novo Nordisk’s American depositary receipts experienced a 1.9% decline in premarket trading but have risen by 48.6% in 2021.